Annovis Bio Reports Synergistic Effect of Lead Compound in Alzheimer’s Disease Model

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company, has released preclinical data showing the synergistic effect of its lead compound, buntanetap, when combined with the GLP-1 agonist dulaglutide in a mouse model of Alzheimer’s disease. The results indicate that the two compounds together enhanced cognitive function beyond levels seen in healthy controls, offering promise for more effective treatment options for patients. Annovis Bio is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s and Parkinson’s, with an innovative approach targeting multiple neurotoxic proteins to restore brain function and improve patients’ quality of life.